ABSTRACT
BACKGROUND: Number of studies has been performed to investigate the association of NAD (P) H quinine oxidoreductase 1 (NQO1) rs1800566 polymorphism with risk of bladder and prostate cancers, but presented inconsistent results. Therefore, we performed a meta-analysis to provide a comprehensive data on the association of NQO1 rs1800566 polymorphism with bladder and prostate cancers. METHODS: All eligible studies were identified in PubMed, Google Scholar, EMBASE, and China National Knowledge Infrastructure databases before June 01, 2019. RESULTS: A total of 22 case-control studies including 15 studies with 4,413 cases and 4,275 controls on bladder cancer and 7 studies with 762 cases and 1,813 controls on prostate cancer were selected. Overall, pooled data showed that the NQO1 rs1800566 polymorphism was significantly associated with an increased risk of bladder cancer (T vs. C: OR 1.300; 95% CI 1.112-1.518; P = 0.001; TT vs. CC: OR 1.415; 95% CI 1.084-1.847; P = 0.011; TC vs. CC: OR 1.389; 95% CI 1.111-1.738; P = 0.004; TT + TC vs. CC: OR 1.428; 95% CI 1.145-1.782; P = 0.002) and prostate cancer (TC vs. CC: OR 1.276; 95% CI 1.047-1.555; P = 0.016; TT + TC vs. CC: OR 1.268; 95% CI 1.050-1.532; P = 0.014). The stratified analysis by ethnicity revealed an increased risk of bladder cancer among Caucasians and prostate cancer among Asians. CONCLUSION: This meta-analysis suggested that the NQO1 rs1800566 polymorphism was significantly associated with increased risk of bladder and prostate cancers.
Subject(s)
NAD(P)H Dehydrogenase (Quinone)/genetics , Prostatic Neoplasms/genetics , Urinary Bladder Neoplasms/genetics , Case-Control Studies , Humans , Male , Polymorphism, Single NucleotideABSTRACT
BACKGROUND: To date, several studies have been carried out on the association of TNF-α -308G>A with the risk of cervical cancer (CC) and breast cancer (BC). However, their conclusions were not consistent. Thus, we performed a comprehensive meta-analysis to evaluate the association more precisely from all eligible case-control studies. METHODS: We searched the PubMed, Google Scholar and Cochrane Library databases systematically to identify relevant studies up to 1 February 2019. The pooled odds ratio (OR) with 95% confidence interval (CI) was calculated using a fixed-or random-effects model. RESULTS: A total of 40 case-control studies including 20 studies with 4,780 cases and 4,620 controls on CC and 20 studies with 12,390 cases and 14,910 controls on BC were selected in this meta-analysis. The pooled results showed that the TNF-α -308G>A polymorphism was significantly associated with an increased risk of CC (A vs. G: OR 1.277; 95% CI 1.104-1.477; P = 0.001; AA vs. GG: OR 1.333; 95% CI 1.062-1.674; P = 0.013; AG vs. GG: OR 1.307; 95% CI 1.064-1.605; P = 0.011; and AA + AG vs. GG: OR 1.324; 95% CI 1.104-1.587; P = 0.002) and BC (AA vs. AG + GG: OR 0.094; 95% CI 0.058-0.152; P 0.001). In the stratified analyses by ethnicity, the TNF-α -308G>A polymorphism was significantly associated with the risk of CC (in Caucasians and Africans) and BC (Caucasians and Asians). CONCLUSION: Our findings showed that TNF-α -308G>A polymorphism may be a risk factor for cervical cancer and breast cancer overall and by ethnicity.
